All In Biotech

NDA 218010 · Glaukos

Idose Tr

Travoprost · Intracameral · Prostaglandin Analog

Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Dec 13, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

137

36 Phase 3, 4 recruiting

FAERS reports

118

19 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 18, 2026.

iDose ® TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). iDose ® TR is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) ( 1 )

Mechanism: Travoprost free acid, a prostaglandin analog is a selective FP prostanoid receptor agonist, which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • IDOSE TR · TRAVOPROST 75MCG · IMPLANT, INTRACAMERAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Travoprost" as an intervention, any sponsor and status, largest first.

All 137 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • medical device removal32
  • intraocular pressure increased27
  • device dislocation18
  • eye pain17
  • eye inflammation13
  • cystoid macular oedema12
  • iritis12
  • photophobia8
  • vision blurred7
  • corneal oedema6
  • hyphaema5
  • ocular hyperaemia5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202410
202547
202661

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 206 on PubMed

Sponsor: Glaukos

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.